Status:

COMPLETED

Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa

Lead Sponsor:

The Wistar Institute

Conditions:

HIV Infections

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

HIV infected people often must take anti-HIV drugs for long periods, leading to long-term drug exposure and toxicity. Interruptions in anti-HIV therapy, also known as structured treatment interruption...

Detailed Description

Long-term toxicity and the high cost of medications are two problems faced by HIV infected people taking ART. Previous studies in HIV-infected patients suggest that ART with STIs may decrease drug exp...

Eligibility Criteria

Inclusion

  • HIV infected
  • CD4 count of 200 to 350 cells/mm3 within 60 days of starting study treatment
  • Antiretroviral naive. Participants who have received antiretrovirals through postexposure prophylaxis or short course therapy to prevent mother-to-child transmission are eligible for this study.
  • Willing to adhere to study treatment
  • Willing to be followed for the duration of this study

Exclusion

  • History of AIDS-defining illness (CDC category C). Patients with a history of pulmonary tuberculosis are not excluded.
  • Newly diagnosed AIDS-defining opportunistic infection or other condition requiring acute therapy at study entry
  • Previous therapy with agents with significant myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic, or cytotoxic potential within 30 days prior to study entry
  • History of immunomodulatory therapy within 4 weeks prior to screening, or cannot abstain from immunomodulators during the study
  • Previously received rabies vaccine
  • Current alcohol or drug abuse that, in the opinion of the investigator, may interfere with the study
  • Diarrhea (more than 6 stools per day for 7 consecutive days) within 30 days prior to study entry
  • Active or suspected acute hepatitis within 30 days of study entry
  • Bilateral peripheral neuropathy of Grade 2 or higher at screening
  • Inability to tolerate oral medication
  • Any clinical condition that, in the opinion of the investigator, would interfere with the study
  • Pregnancy or breastfeeding

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2010

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT00100646

Start Date

March 1 2007

End Date

March 1 2010

Last Update

August 27 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of the Witwatersrand

Johannesburg, South Africa